JHS Svendgaard Laboratories Ltd (NSE: JHS, BSE: 532771) is a New Delhi, Delhi-based company in the Dental Care Products industry. With a market capitalisation of ₹72 Cr, it ranks #3,425 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 2 in Dental Care Products. At ₹8.30 (as of 10 Nov 2026), the share price is 39.4% below its 52-week high of ₹13.69 and 32.6% above its 52-week low of ₹6.26. The share price is down 36.3% over one year and up 3.8% over three months.
| Current Price | ₹8.30 |
|---|---|
| Market Cap | ₹72 Cr |
| NSE Symbol | JHS |
| BSE Code | 532771 |
| Sector | Consumer Staples > Household and Personal Products > Personal Care Products |
| Sub-Industry | Personal Care Products > Dental Care Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -1.11% |
| Return on Assets | -1.20% |
| 52-Week Range | ₹6.26 – ₹13.69 |
| 1-Year Price Change | -36.3% |
| 3-Month Price Change | +3.8% |
| Beta (1Y) | 0.8 |
| Dividend Yield | 0.00% |
| Headquarters | New Delhi, Delhi |
| Website | www.svendgaard.com |
| Revenue | ₹22 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 2.3% |
| EPS (Basic) | ₹0.06 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
JHS Svendgaard Laboratories Ltd reported revenue of ₹22 Cr in Q2 FY27, down 2.0% from ₹22 Cr in Q2 FY26 and down 28.1% from ₹30 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net loss of ₹0 Cr in Q2 FY26. Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹22 Cr (Q2 FY27) to ₹33 Cr (Q4 FY26). The company reported a net loss in 2 of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹22 Cr | ₹1 Cr | 2.3% |
| Q1 FY27 | ₹30 Cr | ₹1 Cr | 3.6% |
| Q4 FY26 | ₹33 Cr | −₹4 Cr | −10.9% |
| Q3 FY26 | ₹23 Cr | ₹1 Cr | 3.4% |
| Q2 FY26 | ₹22 Cr | −₹0 Cr | −0.9% |
| Q1 FY26 | ₹23 Cr | ₹1 Cr | 4.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 33.85% of JHS Svendgaard Laboratories Ltd's shares as of Sept 2026, against 34.56% in Dec 2025 (−0.71 percentage points).
JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures, trades in, and sells a range of oral and dental products in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, whitening gels, talcum powders, sanitizers, detergents, and denture tablets. It also provides contract manufacturing services for oral care products. In addition, the company exports its products. JHS Svendgaard Laboratories Limited was founded in 1997 and is based in New Delhi, India.
1. Manufacturing Business-This segment manufactures and sells a range of oral and dental products for adults and kids. 2. Other than Manufacturing-This segment provides contract manufacturing services for oral care products of other brands; and operates a chain of dental clinics. 3. Retail Business-This segment is involved in retail trade in stores. It also sells its products through its Website, aquawhite.in. 4. Inter Segment Revenue-0
1. Manufacturing of Oral Care Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| JHS Svendgaard Laboratories Ltd | ₹72 Cr | n/m | -1.11% | ₹22 Cr | -36.3% |
| Novateor Research Laboratories L | ₹0 Cr | 252.9 | 0.85% | — | +25.2% |
Listed by market capitalisation. Ratios are shown for context only.
JHS Svendgaard Laboratories Ltd is trading at ₹8.30, with a market capitalisation of ₹72 Cr.
JHS Svendgaard Laboratories Ltd operates in the Consumer Staples > Household and Personal Products > Personal Care Products space (Personal Care Products > Dental Care Products).
JHS Svendgaard Laboratories Ltd has a return on equity of -1.11%.
JHS Svendgaard Laboratories Ltd is listed on the NSE under the symbol JHS and on the BSE under the scrip code 532771.
JHS Svendgaard Laboratories Ltd's share price is down 36.3% over one year and up 3.8% over three months. Its 52-week range is ₹6.26 to ₹13.69.
In Q2 FY27, JHS Svendgaard Laboratories Ltd reported revenue of ₹22 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.06 (consolidated, parsed from the company's exchange filing).
JHS Svendgaard Laboratories Ltd reported revenue of ₹22 Cr in Q2 FY27, down 2.0% from ₹22 Cr in Q2 FY26 and down 28.1% from ₹30 Cr in Q1 FY27.
Promoters held 33.85% of JHS Svendgaard Laboratories Ltd's shares as of Sept 2026, against 34.56% in Dec 2025 (−0.71 percentage points).
Data as of 10 Nov 2026. Descriptive market data only — not investment advice.